About Clinical Trials of Small Cell Lung Cancer

Clinical trials are research studies that involve testing new drugs and other related treatments among individuals—comparing the standard therapy with others is done in the clinical trials that may provide better outcomes. The conduction of clinical trials has been considered as the best method towards the newest cancer treatment. It has been helpful for doctors to find better ways to treat small-cell lung cancer. If the patient’s doctors can find the specific type of cancer their patient has, they are supposed to go for the clinical trial. Even if the patient chooses to participate in the clinical trial, they have the right to withdraw their participation at any point in time. 

Clinical trials have been considered a crucial phase among individuals suffering from small cell lung cancer for two main reasons. The individuals participating in the clinical trials have been observed to contribute tumor and blood for conducting further research study applying not only to those clinical trials that they have been enrolled in but also to those whose future studies will be done. Hence, the individuals are specifically contributing to the broader aspects of future development towards treating small cell lung cancer ​1​

The second essential component of the clinical trial involves the evaluation of the new drug efficacy within the individuals and observing the fact that the newly developed drug is capable of controlling small cell lung cancer more effectively. Therefore, the clinical trials result in the development of new therapies for small cell lung cancer that helps in improving the outcome in treating the patients. It has been complicated to achieve better outcomes with many clinical trials in small cell lung cancer. And with these difficulties in representing the improvement of outcomes for patients suffering from small cell lung cancer, the argument continues that if not more important to have more patient specimens for conducting the study and learning from so that can pass this information on to different clinical trials in the future.

Different groups of targeted therapies that are the pills or non-chemotherapy, non-immunotherapy treatment options among the patients with small cell lung cancer have still been considered under the developmental phase ​2​. The broader aspects into which they fit have tended to block cell growth through epigenetic modification, which refers to a comprehensive cell growth modality or blocking pills to block the specific cell cycle. The mechanism of every category of the targeted therapy is being evaluated among the patients diagnosed with small cell lung cancer. But still, the research is being conducted to integrate the use of pills that are being targeted for cancer compared with the normal cells among the individuals suffering from small cell lung cancer. 

The clinical trials regarding the targeted therapies among the individuals suffering from small cell lung cancer tend to move towards specific applications of the targeted therapies. The data of clinical trials are used for such patients whose tumor shrinkage was not evaluated. Also, the subgroups of small-cell lung cancer patients have been categorized and have shown effectiveness in the outcome after conducting the targeted therapies in the clinical trial. Hence, the undertaken therapies’ efficacy helps determine the treatment efficacy by comparing the treatment therapies. 

The clinical trials on monitoring the small cell lung cancer within the bloodstream have been integrated to improve care among the patients. Hence, blood cells and liquid biopsies have been conducted to monitor the small cell lung cancer among the patients. This clinical trial has provided helpful insights towards the management of small cell lung cancer, which can integrate among the small cell lung cancer patients who have undergone surgery, and the blood test can be effective in analyzing the borderline cases of small cell lung cancer patients who are capable of undergoing surgery. Everything from individuals with recurrent small cell lung cancer receiving chemotherapy can be practical in subgroups but shows no efficacy. The clinical trials have integrated the checking by CAT scan for two months after every treatment. The appropriate outcome among the patients after receiving even one dose of chemotherapy is monitored in the clinical trials. The pros and cons regarding the continuation of the treatment while understanding the possible side effects that the individuals and their families need to know for informed decision making.

One of the most common approaches for the clinical trial for the past year is the efficacy of using immunotherapy and the individuals with small cell lung cancer being treated for complete cure. Therefore, the individuals receiving chemotherapy and radiation have undergone immunotherapy with the essential goal of increasing the cure rates. These trials have been running for the past few years. The individuals volunteer for clinical trials as these studies have contributed to minor cell lung cancer treatment. If the individuals are not directly gaining any benefits from the clinical trials, their participation tends to show advantages in the upcoming future with small cell lung cancer. 

References 

  1. 1.
    Byers LA, Rudin CM. Small cell lung cancer: Where do we go from here? Cancer. Published online October 21, 2014:664-672. doi:10.1002/cncr.29098
  2. 2.
    Cottin V, Arpin D, Lasset C, et al. Small-cell lung cancer: Patients included in clinical trials are not representative of the patient population as a whole. Annals of Oncology. Published online July 1999:809-816. doi:10.1023/a:1008399831512